Skip to main content
OpenTrials
Completed

NCT Number: NCT04628169

Impact of Netrin-1 in the Pathophysiology of Placenta Accreta Spectrum

The main goal of this study is to assess the role of Netrin 1, neogenin and ZEB1 in PAS-associated invasion

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pathophysiology of Placenta Accreta

Age range

20 year–40 year

Sex eligibility

Female

Study type

Observational

Primary location

Hanaa Mohammed Mohammed Sayed

Asyut, Egypt

About this study

  • To evaluate the immunohistochemical expression of these proteins in PAS specimens in comparison with the control placental tissues.
  • To correlate their expression with the demographic parameters.
  • To assess the correlation between their expression in PAS specimens.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • PAS patients who underwent hysterectomy to allow proper pathologic grading of PAS

Exclusion criteria

  • patients with fundal and middle anterior or posterior placenta,
  • pregnancy associated with morbid conditions such as hypertension, diabetes mellitus, autoimmune disease, cardiac disease, renal disease, history of anemia, blood transfusion, other blood diseases and endocrinal disease; fetal distress or intrauterine growth retardation.
  • uterine scar pregnancies were excluded

Treatment and study plan

no intervention applied

Other

no intervention applied

Primary outcomes

  1. impact of netrin-1 in the pathophysiology of placenta accreta spectrum

    Time frame: baseline

    • Evaluation of the immunohistochemical expression of netrin 1 in PAS specimens in comparison with the control placental tissues.
    • Evaluation of the immunohistochemical expression of neogenin in PAS specimens in comparison with the control placental tissues
    • Evaluation of the immunohistochemical expression of ZEB1 in PAS specimens in comparison with the control placental tissues.
    • Correlate their immunohistochemical expression with the demographic parameters and assess the correlation between their expression in PAS specimens.

Sponsors and collaborators

Lead sponsor

Assiut University

Other

Registry information

Important dates

Study start
2021
Primary completion
2023
Study completion
2023
First posted
Nov 13, 2020
Registry last updated
Sep 20, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.